Iron deficiency anemia (IDA) continues to be a global public health concern, mostly in the developing countries. However, precise epidemiological data on childhood IDA in Croatia are lacking. In order to establish its frequency, underlying etiologies, the rationale for tertiary care visits, diagnostic practices, and current treatment regimens of IDA, medical records of children referred to pediatric hematologists for iron deficiency in a five-year period at tertiary institutions (Zagreb, Rijeka, Split, Osijek) throughout Croatia were retrospectively analyzed. Eight hundred and sixty-four children, predominately of preschool age, were referred mainly by the primary care pediatricians, who, in general, performed basic diagnostics but failed to initiate oral iron therapy in half of the patients. Approximately one-third of patients were symptomatic, with inadequate nutrition prevailing as underlying etiology. Dextriferron was the preferred iron formulation among hematologists, with a median dose of 5 mg/kg, with acceptable compliance rates (63.5–93.2%). Hospital admission rates varied among the centers (9.4–35%), and so did transfusion policies (6.4–22.9%). The greatest difference was observed in the frequency of parenteral iron administration (0.3–21.5%). In conclusion, the burden of childhood IDA, even in a high-income country, remains substantial, necessitating consistent implementation of national guidelines and additional education of primary health care providers.

Introduction: The use of complementary and alternative medicine (CAM) has become a customary practice among pediatric cancer patients worldwide. The frequency of its use by pediatric cancer patients in Croatia has not been previously determined. Methodology: In order to establish the frequency and detect factors affecting the use of CAM, a single-center, observational, cross-sectional study was conducted at the Children's Hospital Zagreb during a two-year period. The patients' parents and caregivers were offered an anonymous, multi-item questionnaire that collected socio-economic and clinical data, as well as details on CAM and dietary supplement practice. Results: Almost half of the participants reported CAM and more than two-thirds reported dietary supplement consumption, predominantly in the intensive phase of the treatment. Factors regarding children or parents had no effect on CAM and supplement utilization. Herbal medicine, vitamins, and minerals were among the most commonly used items. Every 10th child experienced at least one adverse event during CAM and supplement use. Conclusion: Awareness of the CAM and dietary supplement application in pediatric oncology patients needs to be raised due to the potential interactions with conventional treatment modalities. For this reason, it is extremely important to inform parents and caregivers of pediatric oncology patients about the use of CAM and dietary supplements to predict and mitigate the occurrence and intensity of the side effects. In the majority of our cases, the patient's guardians informed the healthcare professionals about the CAM and supplement implementation in their children, therefore, they were offered additional information about the possible negative impact of CAM and supplement use on standard medical care in a timely manner.

Invasive fungal infections (IFI) are life-threatening complications of intensive chemotherapy treatment, with the incidence in pediatric patients ranging from 2% to 21%. In this article, we describe our 5-year experience of IFI in pediatric oncolog...

Survival rates for children treated for malignant diseases continue to improve, yet many survivors face persistent late oral complications that affect function, aesthetics, and quality of life. Oncological therapy, especially at a young age and following head and neck radiotherapy or intensive chemotherapy, can disrupt dental and craniofacial development, resulting in dental developmental disorders, enamel defects, salivary gland dysfunction, caries susceptibility, periodontal problems, trismus, and osteoradionecrosis of the jaw. Although these effects are partially known, they are frequently underrecognized in routine practice, and many children do not receive adequate long-term dental follow-up. A key challenge highlighted in the recent literature is the absence of structured, evidence-based guidelines for monitoring and managing late oral effects. The article emphasizes the need for clearer recommendations, better communication of oncological treatment histories, and stronger integration of dental professionals within survivorship care. Developing standardized follow-up protocols will be essential to ensure timely detection, consistent management, and improved oral health outcomes for childhood cancer survivors. This article is intended as a narrative review, synthesizing available evidence from key publications to highlight clinically relevant late oral complications and gaps in current survivorship care.

Survival rates for children treated for malignant diseases continue to improve, yet many survivors face persistent late oral complications that affect function, aesthetics, and quality of life. Oncological therapy, particularly when administered early in childhood, can disrupt dental and craniofacial development, resulting in dental developmental disorders, enamel defects, salivary gland dysfunction, caries susceptibility, periodontal problems, trismus, and osteoradionecrosis of the jaw. Although these effects are partially known, they are frequently underrecognized in routine practice, and many children do not receive adequate long-term dental follow-up. A key challenge highlighted in recent literature is the absence of structured, evidence-based guidelines for monitoring and managing late oral effects. The article emphasizes the need for clearer recommendations, better communication of oncological treatment histories, and stronger integration of dental professionals within survivorship care. Developing standardized follow-up protocols will be essential to ensure timely detection, consistent management, and improved oral health outcomes for childhood cancer survivors.

Our goal was to describe demographic characteristics, course and outcome of neutropenic patients. We used descriptive statistics to demonstrate demographic and clinical characteristics of patients who were referred to pediatric hematologist’s examination or hospitalized in the Department of Hematology and Oncology, Children’s Hospital Zagreb, due to neutropenia from January 1st, 2009 to December 31st, 2019. Oncology patients with febrile neutropenia were excluded from the study. Altogether, 100 children were examined or hospitalized in our Department during the 11-year period due to neutropenia, of which 56 were males, with an average age of 3.48 years. The cause of a low absolute neutrophil count (ANC) was autoimmune neutropenia in 37 patients, 31 had chronic idiopathic neutropenia, 27 had infectious neutropenia, 3 had cyclic neutropenia, while 2 were diagnosed with alloimmune neonatal neutropenia. The mean value of ANC at presentation was 732/mm3, and the mean lowest ANC detected during disease course was 600/mm3. Among the 5 diagnostic subgroups, both values were the lowest in patients with cyclic neutropenia in which mean ANC at presentation was 420/mm3 and mean lowest ANC detected during disease course was 180/mm3. Granulocyte colony-stimulating factor (GCS-F) was given to only 3 patients, whose mean ANC at presentation was 140/mm3. Besides the laboratory finding of persistent severe neutropenia, all 3 patients were prone to recurrent infections. Twenty-three patients had additional cytopenia, out of which 4 had pancytopenia, 13 had anemia and 6 patients had thrombocytopenia. Among patients with additional cytopenia, 5 had positive anti-granulocyte antibodies (21.7%). The mean time to disease resolution was 10.2 months, being the longest in the cyclic neutropenia subgroup, while patients with infectious neutropenia mainly recovered after 21.3 days. The mean follow-up time was 1.6 years. According to data from our Department, neutropenia is most commonly diagnosed in pre-school children, boys being more frequently affected than girls. More than one third of patients have positive anti-granulocyte antibodies. However, the condition is usually benign, it resolves mainly spontaneously in less than a year, and patients generally do not require G-CSF.